Three medicines treating HIV, pain and cancer have been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its latest meeting.
Read More
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.
Read More
European regulators are now reviewing Gilead’s fixed-dose combination of bictegravir (BIC), emtricitabine and tenofovir alafenamide as a treatment for HIV-1 infection.
Read More
Patients with chronic hepatitis B in Europe have gained the first new treatment option in nearly 10 years following the approval of Gilead’s Vemlidy.
Read More
Janssen-Cilag has submitted a marketing application to the European Medicines Agency for a new once-daily darunavir-based single tablet regimen (STR) to treat HIV.
Read More
